On 16 December 2014, orphan designation (EU/3/14/1386) was granted by the European Commission to Aprea AB, Sweden, for 2-hydroxymethyl-2-methoxymethyl-1-azabicyclo[2,2,2]octan-3-one (also known as APR-246) for the treatment of ovarian cancer.
In March 2017, Aprea AB changed name to Aprea Therapeutics AB.
The sponsor’s address was updated in October 2020.
|Disease / condition||
Treatment of ovarian cancer
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.